Table of contents:
Latest news & events
Featured presentation
In our own words
IR HOME
News & Events
Press releases
Events
Presentations
Financials
SEC filings
Analyst coverage
Stock info
Quote & chart
History & investment calculator
Governance
Management
Board of directors
Governance documents
Committee composition
Resources
Investor contact
Online investor kit
FAQs
RSS feeds
MENU
Investor Relations
Latest
January 14, 2021
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
READ MORE
NYSE: NVTA
52.59
-
0.85
-
1.59%
Volume:
4,120,641
20 minute delay
January 15, 2021
IR HOME
News & Events
Press releases
Events
Presentations
Financials
SEC filings
Analyst coverage
Stock info
Quote & chart
History & investment calculator
Governance
Management
Board of directors
Governance documents
Committee composition
Resources
Investor contact
Online investor kit
FAQs
RSS feeds
INVITAE HOME
Latest
January 14, 2021
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
READ MORE
NYSE: NVTA
52.59
-
0.85
-
1.59%
Volume:
4,120,641
20m delay
January 15, 2021
Latest news & events
Feature presentation
Events
In our own words
Thumb
Download
Invitae’s mission
What sets us apart
How we’ll do it
Impact on patients
Investor Toolkit
Email Alerts
Sign up to receive Invitae financial information by email.
Email Address:
*
I'D LIKE TO RECEIVE EMAILS ABOUT:
*
Press Release
SEC Filing
Presentation
Event
End of Day Stock Quote
Enter the code shown above.
Investor Contact
1400 16th St.
San Francisco, CA, 94103
Email:
ir@invitae.com
Privacy
|
Terms
|
Licensing
|
Contact
© Invitae Corporation. All rights reserved.
Powered By Q4 Inc.
5.49.0.3